Cholinergic vesicular transporters in progressive supranuclear palsy

Neurology

Volumn 58, Issue 7, 2002, Pages 1013-1018

  Suzuki, Masahiko ^a,e   Desmond, Timothy J ^c   Albin, Roger L ^b,d   Frey, Kirk A ^a,b,c,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; CHOLINE ACETYLTRANSFERASE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ARTICLE; BASAL GANGLION; BINDING SITE; CAUDATE NUCLEUS; CHOLINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; INTERNEURON; NERVE DEGENERATION; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

EID: 0037046197     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.7.1013     Document Type: Article

References (54)

1. Progressive supranuclear palsy
2. Progressive supranuclear palsy
3. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
4. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: A clinicopathological study
5. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging
6. Allocortical neurofibrillary changes in progressive supranuclear palsy
7. Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: A quantitative analysis of six cases
8. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): A reappraisal
9. Dopaminergic and cholinergic lesions in progressive supranuclear palsy
10. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy
11. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy
12. Clinical progressive supranuclear palsy: Differential diagnosis by IBZM-SPECT and MRI
13. The neuropathology of progressive supranuclear palsy
14. Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy
15. PET measures of benzodiazepine receptors in progressive supranuclear palsy
16. Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers
17. Brain monoamines in progressive supranuclear palsy-comparison with idiopathic Parkinson's disease
18. 3H]GBR 12935 binding to dopamine uptake sites: Subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy
19. 3H]mazindol
20. Cholinergic and peptidergic systems in PSP
21. Large neurons in the neostriatum in Alzheimer's disease and progressive supranuclear palsy: A topographic, histologic and ultrastructural investigation
22. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study
23. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
24. 3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity
25. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy
26. Expression of the vesicular acetylcholine transporter is unaltered by pharmacological interventions in cholinergic transmission
27. 3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography
28. A rapid radiochemical method for the determination of choline acetyltransferase
29. Measurement of protein using bicinchoninic acid
30. Acetylcholine
31. 3H]-piperidino) cyclohexanol
32. Suppression of in vivo neostriatal acetylcholine release by vesamicol: Evidence for a functional role of vesamicol receptors in brain
33. 3H-hemicholinium-3 binding sites in rat brain: A potential second-messenger role for fatty acids in the regulation of highaffinity choline uptake
34. Autoradiographic quantification of the vesamicol receptor in Alzheimer's disease
35. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease
36. Vesicular neurotransmitter transporters in Huntington's disease
37. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183)
38. 3H]vesamicol binding in brain: Autoradiographic distribution, pharmacology, and effects of cholinergic lesions
39. Synthesis, in vitro acetylcholine storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol)
40. Purification and characterization of a nonvesicular vesamicol-binding protein from electric organ and demonstration of a related protein in mammalian brain
41. 18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses
42. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol
43. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM
44. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease
45. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography
46. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia
47. Cholinergic enzyme systems in Parkinson's disease
48. Reduced cerebral cortical but elevated striatal concentration of somatostatinlike immunoreactivity in dominantly inherited olivopontocerebellar atrophy
49. Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy
50. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease
51. 18F-dopa PET data
52. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
53. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease
54. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease